ReviR Therapeutics Initiates Phase 1 Trial of RTX-117 for Rare Neurological Diseases
核心洞察
ReviR Therapeutics (搜索) has dosed the first participant in a Phase 1 clinical trial of RTX-117 (搜索), a potential first-in-class therapy for Charcot-Marie-Tooth disease (搜索) and Vanishing White Matter disease (搜索).
RTX-117 (搜索) targets the Integrated Stress Response pathway (搜索) by activating eIF2B (搜索) to restore protein translation homeostasis and was discovered using AI-driven drug discovery platforms.
The investigational drug has received IND clearance from both the U.S. FDA and China's NMPA, along with FDA Orphan Drug Designation for CMT.
ReviR Therapeutics (搜索) has achieved a significant clinical milestone by dosing the first participant in a Phase 1 trial of RTX-117 (搜索), an investigational small molecule therapy targeting two rare neurological disorders with no approved disease-modifying treatments. The randomized, double-blind, placebo-controlled, dose-escalation trial is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of RTX-117 in healthy participants.
Targeting Critical Unmet Medical Needs
RTX-117 (搜索) is being developed for Charcot-Marie-Tooth disease (搜索) (CMT) and Vanishing White Matter disease (搜索) (VWM), both representing significant unmet medical needs. CMT affects approximately 1 in 2,500 people worldwide and is characterized by progressive peripheral neuropathy that can lead to muscle weakness, atrophy, and sensory loss, with some subtypes leading to high mortality rates. VWM is a rare, often fatal pediatric leukodystrophy associated with progressive neurological decline.
The investigational therapy has received dual regulatory clearance, with Investigational New Drug (IND) approval from both the U.S. Food and Drug Administration and China's National Medical Products Administration Center for Drug Evaluation. Additionally, RTX-117 (搜索) has received FDA Orphan Drug Designation for CMT, making it currently the only pipeline in China granted IND clearance for both CMT and VWM.
AI-Driven Drug Discovery Approach
RTX-117 (搜索) represents a potential first-in-class, orally administered small molecule designed to modulate the Integrated Stress Response (ISR) pathway. The therapy works by activating eIF2B (搜索), a key protein translation initiation factor, with the goal of restoring protein translation homeostasis implicated in both target diseases.
The drug candidate was discovered and developed using ReviR's proprietary VoyageR AI platform in collaboration with XtalPi (搜索)'s AI and robotics drug discovery engine. By leveraging deep insights into RNA biology and protein translation homeostasis, the platform enabled rapid progression from algorithmic design to clinical testing.
"RTX-117 (搜索)'s progress exemplifies how AI-driven precision drug discovery overcomes traditional economic barriers in rare disease R&D," said Dr. Shuhao Wen, Chairman of XtalPi (搜索). "Our platform's ability to rapidly translate biological discoveries into clinical candidates opens new frontiers for patients and partners."
Clinical Development Strategy
The Phase 1 study is being conducted in China and will support future studies in patients with CMT and VWM. The milestone marks the clinical entry of what could be the first disease-modifying therapy for these conditions.
"The initiation of dosing in our first-in-human study, coupled with the dual IND clearance in China, marks a transformative leap for ReviR Therapeutics (搜索)," said Peng Yue, PhD, CEO of ReviR. "By leveraging our VoyageR AI platform and our integrated cross-border operations in the U.S. and China, we are accelerating the development of our small molecule pipelines designed to address critical gaps where no approved disease-modifying treatments exist."
Paul August, PhD, Chief Scientific Officer of ReviR, emphasized the significance of the regulatory clearances: "The milestone is a testament to the rigor of our preclinical data and the efficiency of our global team. We are committed to working closely with clinical investigators and patient organizations in China to bring these innovative therapies forward as safely and rapidly as possible."
Platform Technology and Future Applications
Beyond RTX-117 (搜索), ReviR's VoyageR AI platform serves as a precision medicine engine, identifying chemical starting points based on their specific impact on RNA splicing. This approach enables the modulation of protein expression at the genetic source, potentially targeting complex neurological conditions and immune and inflammatory pathways that have long been considered "undruggable."
XtalPi (搜索) and ReviR are advancing multiple collaborative programs, aiming to systematically tackle rare diseases with high unmet need. The success of RTX-117 (搜索) validates the scalability and clinical impact of AI and robotics in expanding treatment options for underserved patient populations.